Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Centralized Switch Process Needs Longer Exclusivity, More Trust - Execs

This article was originally published in The Tan Sheet

Executive Summary

Limited data protection and a lack of trust between industry and regulators are dampening enthusiasm for the European Union's centralized switch process, according to industry leaders

You may also be interested in...



Phased Rx Drug Approval In Europe Could Help Switches – EU Execs

Phased Rx Drug Approval In Europe Could Help Switches – EU Execs

GSK Urges Regulatory Changes To Pull EU Market From Doldrums

The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.

Related Content

Topics

UsernamePublicRestriction

Register

PS104245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel